Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

Vashti Irani, Andrew J. Guy, Dean W Andrew, James G. Beeson, Paul A. Ramsland, Jack S. Richards

Research output: Contribution to journalReview ArticleResearchpeer-review

104 Citations (Scopus)

Abstract

Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.

Original languageEnglish
Pages (from-to)171-182
Number of pages12
JournalMolecular Immunology
Volume67
Issue number2
DOIs
Publication statusPublished - 1 Oct 2015

Keywords

  • Antibody-dependent effector mechanisms
  • IgG subclasses
  • Infectious diseases
  • Therapeutic antibodies

Cite this

@article{ab67fe0d4aab4af5805c545cf141b06e,
title = "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases",
abstract = "Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.",
keywords = "Antibody-dependent effector mechanisms, IgG subclasses, Infectious diseases, Therapeutic antibodies",
author = "Vashti Irani and Guy, {Andrew J.} and Andrew, {Dean W} and Beeson, {James G.} and Ramsland, {Paul A.} and Richards, {Jack S.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1016/j.molimm.2015.03.255",
language = "English",
volume = "67",
pages = "171--182",
journal = "Molecular Immunology",
issn = "0161-5890",
publisher = "Elsevier",
number = "2",

}

Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. / Irani, Vashti; Guy, Andrew J.; Andrew, Dean W; Beeson, James G.; Ramsland, Paul A.; Richards, Jack S.

In: Molecular Immunology, Vol. 67, No. 2, 01.10.2015, p. 171-182.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

AU - Irani, Vashti

AU - Guy, Andrew J.

AU - Andrew, Dean W

AU - Beeson, James G.

AU - Ramsland, Paul A.

AU - Richards, Jack S.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.

AB - Monoclonal antibodies are being developed as therapeutics to complement drugs and vaccines or to fill the gap where no drugs or vaccines exist. These therapeutic antibodies (ThAb) may be especially important for infectious diseases in which there is antibiotic resistance, toxin-mediated pathogenesis, or for emerging pathogens. The unique structure of antibodies determines the specific nature of the effector function, so when developing ThAb, the desired effector functions need to be considered and integrated into the design and development processes to ensure maximum efficacy and safety. Antibody subclass is a critical consideration, but it is noteworthy that almost all ThAb that are licenced or currently in development utilise an IgG1 backbone. This review outlines the major structural properties that vary across subclasses, how these properties affect functional immunity, and discusses the various approaches used to study subclass responses to infectious diseases. We also review the factors associated with the selection of antibody subclasses when designing ThAb and highlight circumstances where different subclass properties might be beneficial when applied to particular infectious diseases. These approaches are critical to the future design of ThAb and to the study of naturally-acquired and vaccine-induced immunity.

KW - Antibody-dependent effector mechanisms

KW - IgG subclasses

KW - Infectious diseases

KW - Therapeutic antibodies

UR - http://www.scopus.com/inward/record.url?scp=84939266734&partnerID=8YFLogxK

U2 - 10.1016/j.molimm.2015.03.255

DO - 10.1016/j.molimm.2015.03.255

M3 - Review Article

VL - 67

SP - 171

EP - 182

JO - Molecular Immunology

JF - Molecular Immunology

SN - 0161-5890

IS - 2

ER -